When Sanofi inked a massive lease in Cambridge Crossing for its Genzyme unit last year, the French drugmaker found itself in prime position for another real estate deal.
The move opened up a lot of square footage at Sanofi Genzyme's existing facility in Kendall Square, the hottest address in the Boston biotech hub. And by subleasing that space to gene therapy player Bluebird Bio at a premium, Sanofi stands to make a profit, Boston Globe reports.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,